US · MRK
Merck & Co., Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Rahway, NJ 07033
- Website
- merck.com
Price · as of 2025-12-31
$112.16
Market cap 309.18B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $129.88 | +15.8% |
| Intrinsic Value(DCF) | $89.77 | -19.96% |
| Graham-Dodd Method(GD) | $48.77 | -56.51% |
| Graham Formula(GF) | $68.94 | -38.54% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $22.88 | $36.99 | $329.94 | $0.51 | $25.45 |
| 2012 | $27.25 | $36.38 | $189.92 | $0.00 | $13.45 |
| 2013 | $37.80 | $38.18 | $5.22 | $0.00 | $2.45 |
| 2014 | $38.10 | $46.61 | $5.96 | $5.83 | $18.08 |
| 2015 | $37.27 | $39.31 | $7.50 | $0.00 | $3.21 |
| 2016 | $47.44 | $43.98 | $5.75 | $0.00 | $12.69 |
| 2017 | $41.10 | $41.16 | $4.63 | $0.00 | $7.90 |
| 2018 | $61.30 | $58.89 | $6.23 | $0.00 | $31.90 |
| 2019 | $64.86 | $60.74 | $5.58 | $0.00 | $3.30 |
| 2020 | $60.73 | $54.18 | $6.96 | $0.00 | $39.28 |
| 2021 | $69.20 | $70.70 | $17.53 | $0.00 | $127.78 |
| 2022 | $98.28 | $94.11 | $201.74 | $0.00 | $166.19 |
| 2023 | $115.86 | $69.90 | $98.48 | $0.00 | $1.33 |
| 2024 | $91.22 | $88.31 | $81.52 | $0.00 | $98.94 |
| 2025 | $121.41 | $129.88 | $69.12 | $48.77 | $68.94 |
AI valuation
Our deep-learning model estimates Merck & Co., Inc.'s (MRK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $129.88
- Current price
- $112.16
- AI upside
- +15.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$89.77
-19.96% upside
Graham-Dodd
$48.77
-56.51% upside
Graham Formula
$68.94
-38.54% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MRK | Merck & Co., Inc. | $112.16 | 309.18B | +16% | -20% | -57% | -39% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| ABT | Abbott Laboratories | $116.32 | 202.45B | -26% | -58% | — | -57% | 30.56 | 3.82 | 4.50 | 17.79 | — | 8.83 | 55.51% | 18.16% | 14.72% | 13.07% | 10.95% | 7.76% | 0.29 | 23.60 | 1.58 | 1.02 | 0.57 | -5131.00% | 567.00% | 1644.00% | 3.71% | 0.58 | 13.06% | 2.06% | 63.10% | 3.07% | 25.53 | 27.79 | 4.64 | 5.28 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| TMO | Thermo Fisher Scientific … | $521.11 | 195.79B | -36% | -60% | -86% | -59% | 28.45 | 3.58 | 4.29 | 19.23 | 388.69 | -16.23 | 37.66% | 18.20% | 15.12% | 13.05% | 9.40% | 6.47% | 0.74 | 5.71 | 1.89 | 1.25 | 2.58 | 732.00% | 391.00% | -1340.00% | 3.29% | 0.51 | 7.89% | 0.33% | 9.50% | 1.90% | 27.19 | 35.04 | 4.95 | 2.81 |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- CEO
- Robert Davis
- Employees
- 73K
- Beta
- 0.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($89.77 ÷ $112.16) − 1 = -19.96% (DCF, example).